<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">HARALDSDÓTTIR, KRISTÍN-HULD</style></author><author><style face="normal" font="default" size="100%">INGVAR, CHRISTIAN</style></author><author><style face="normal" font="default" size="100%">STENRAM, UNNE</style></author><author><style face="normal" font="default" size="100%">TRANBERG, KARL-GÖRAN</style></author></authors><secondary-authors></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Long-term Follow-up After Interstitial Laser Thermotherapy of Breast Cancer</style></title><secondary-title><style face="normal" font="default" size="100%">Anticancer Research</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2015</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2015-11-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">6147-6152</style></pages><volume><style face="normal" font="default" size="100%">35</style></volume><issue><style face="normal" font="default" size="100%">11</style></issue><abstract><style  face="normal" font="default" size="100%">Aim: To review the effect of immunological changes induced by interstitial laser thermotherapy (ILT) on long-term outcome of patients with breast cancer. Patients and Methods: Twenty-four patients with invasive breast cancer were treated with ILT followed by standard surgical excision. Immunohistological reactions on immunocompetent cells were performed on specimens obtained before and after ILT. Follow-up time was 116 (range=91-136) months. Results: Significant prognostic factors were histologically-positive axillary lymph nodes and Ki67 positivity. ILT increased cytotoxic T (CD8+) lymphocytes within the tumor and mature dendritic cells (CD83+) and reduced the number of T-regulatory cells (Treg) CD25+/Forkhead box p3+ (FOXP3+) lymphocytes in regional lymph nodes. These changes did not correlate with prognosis. The number of CD8+ cells within the tumor, both before and after treatment, was significantly higher in patients with recurrence than in those without recurrence (p&lt;0.01 and p&lt;0.05, respectively). Patients with recurrent disease had a lower number of CD57+ cells in tumor-free lymph nodes than did patients without recurrence (p&lt;0.05). Conclusion: ILT did not have any long-term adverse effects. The clinical impact of the supposedly favourable immune changes after ILT should be examined in a larger patient population.</style></abstract></record></records></xml>